Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial-Reference-Cited by-同舟云学术

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Published:2023-07 Issue:4 Volume:17 Page:491-503
ISSN:1933-2874
Container-title:Journal of Clinical Lipidology
language:en
Short-container-title:Journal of Clinical Lipidology

Author:

Ballantyne Christie M.,Ditmarsch Marc^ORCID,Kastelein John JP,Nelson Adam J.^ORCID,Kling Douglas,Hsieh Andrew^ORCID,Curcio Danielle L.^ORCID,Maki Kevin C.^ORCID,Davidson Michael H.,Nicholls Stephen J.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference39 articles.

1. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes;Ference;N Engl J Med,2016

2. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Grundy;Circulation,2019

3. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: a review of current practice and recommendations for improved effectiveness;Makover;Am J Prev Cardiol,2022

4. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: a joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology;Virani;J Clin Lipidol,2023

5. Compounding benefits of cholesterol-lowering therapy for the reduction of major cardiovascular events: systematic review and meta-analysis;Wang;Circ Cardiovasc Qual Outcomes,2022

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?;Expert Review of Cardiovascular Therapy;2024-09

2. Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease;JAMA Cardiology;2024-09-01

3. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond;American Journal of Preventive Cardiology;2024-09

4. A Randomized, Parallel, Open‐Label, Single‐Dose and Multiple‐Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China;The Journal of Clinical Pharmacology;2024-08-19

5. Obicetrapib—the Rebirth of CETP Inhibitors?;Current Atherosclerosis Reports;2024-08-16